AU780854B2 - Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy - Google Patents

Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy Download PDF

Info

Publication number
AU780854B2
AU780854B2 AU28061/00A AU2806100A AU780854B2 AU 780854 B2 AU780854 B2 AU 780854B2 AU 28061/00 A AU28061/00 A AU 28061/00A AU 2806100 A AU2806100 A AU 2806100A AU 780854 B2 AU780854 B2 AU 780854B2
Authority
AU
Australia
Prior art keywords
hormone
leu
nucleic acid
ser
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU28061/00A
Other languages
English (en)
Other versions
AU2806100A (en
Inventor
Charlotte Hauser-Funke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octagene GmbH
Original Assignee
Octagene GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107099 external-priority patent/DE19907099A1/de
Application filed by Octagene GmbH filed Critical Octagene GmbH
Publication of AU2806100A publication Critical patent/AU2806100A/en
Application granted granted Critical
Publication of AU780854B2 publication Critical patent/AU780854B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU28061/00A 1999-02-19 2000-02-18 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy Ceased AU780854B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12084899P 1999-02-19 1999-02-19
DE1999107099 DE19907099A1 (de) 1999-02-19 1999-02-19 Hormon-Hormonrezeptorkomplexe und Nukleinsäurekonstrukte und ihre Verwendung in der Gentherapie
DE19907099 1999-02-19
US60/120848 1999-02-19
PCT/EP2000/001368 WO2000049147A1 (en) 1999-02-19 2000-02-18 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005200908A Division AU2005200908A1 (en) 1999-02-19 2005-02-28 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy

Publications (2)

Publication Number Publication Date
AU2806100A AU2806100A (en) 2000-09-04
AU780854B2 true AU780854B2 (en) 2005-04-21

Family

ID=26051947

Family Applications (2)

Application Number Title Priority Date Filing Date
AU28061/00A Ceased AU780854B2 (en) 1999-02-19 2000-02-18 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
AU2005200908A Abandoned AU2005200908A1 (en) 1999-02-19 2005-02-28 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2005200908A Abandoned AU2005200908A1 (en) 1999-02-19 2005-02-28 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy

Country Status (6)

Country Link
EP (1) EP1151099A1 (ja)
JP (1) JP2002537311A (ja)
AU (2) AU780854B2 (ja)
CA (1) CA2362970A1 (ja)
NZ (1) NZ513595A (ja)
WO (1) WO2000049147A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5247400A (en) * 1999-06-14 2001-01-02 Chisso Corporation Substance binding to the substrate of activated blood coagulation factor in competition with this factorto thereby regulate the r eaction between the activated blood coagulation factor and the substrate, a process for producing the substance and blood coagulation
EP1136553A1 (en) * 2000-03-22 2001-09-26 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
MXPA02009221A (es) * 2000-03-22 2005-07-25 Octagene Gmbh Produccion de factores de coagulacion sanguineo recombinantes en lineas celular humanas.
EP1180364A1 (en) * 2000-08-15 2002-02-20 Octagene GmbH Steroid hormones as transfer agents
WO2002028175A2 (en) * 2000-10-03 2002-04-11 Association Pour Le Developpement De La Recherche En Genetique Moleculaire (Aderegem) Transgenic mouse for targeted recombination mediated by modified cre-er
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US20020197670A1 (en) * 2001-06-22 2002-12-26 Price Thomas M. Membrane associated progesterone receptor
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018172A1 (en) * 1993-02-01 1994-08-18 Yoshitomi Pharmaceutical Industries, Ltd. Imidazolylbenzene compound and use thereof as medicine
WO1994028150A1 (en) * 1993-05-21 1994-12-08 Mcgill University Expression vectors responsive to steroid hormones

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206874D0 (en) * 1992-03-30 1992-05-13 Connaught Lab Generation of improved inducible mammalian expression vectors
JPH07509694A (ja) * 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
AU6087694A (en) * 1993-01-26 1994-08-15 Research Institute of the Palo Alto Medical Foundation, The The l-plastin promoter region and its uses
ATE322547T1 (de) * 1993-06-10 2006-04-15 Genetic Therapy Inc Adenovirale vektoren für die behandlung der hämophilie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018172A1 (en) * 1993-02-01 1994-08-18 Yoshitomi Pharmaceutical Industries, Ltd. Imidazolylbenzene compound and use thereof as medicine
WO1994028150A1 (en) * 1993-05-21 1994-12-08 Mcgill University Expression vectors responsive to steroid hormones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NORDEEN S K ET AL. MOL ENDICOINOL, 1998:12(6):891-8 *

Also Published As

Publication number Publication date
AU2005200908A1 (en) 2005-03-24
JP2002537311A (ja) 2002-11-05
WO2000049147A1 (en) 2000-08-24
NZ513595A (en) 2001-09-28
AU2806100A (en) 2000-09-04
EP1151099A1 (en) 2001-11-07
CA2362970A1 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
CN108753824B (zh) 用于治疗视网膜营养不良的病毒载体
CN111344395B (zh) 产生经修饰的自然杀伤细胞的方法及使用方法
AU2024216517A1 (en) Enhanced systems for cell-mediated oncolytic viral therapy
KR101470472B1 (ko) 장기 지속형 약물 제형
AU774643B2 (en) Compositions and methods for use in recombinational cloning of nucleic acids
KR20210149060A (ko) Tn7-유사 트랜스포존을 사용한 rna-유도된 dna 통합
KR101471445B1 (ko) 조류에서 이식유전자 발현
KR20200064129A (ko) 트랜스제닉 선택 방법 및 조성물
KR20180088484A (ko) 프롤린 및 알라닌 잔기가 풍부한 반복적인 아미노산 서열을 암호화하고 낮은 반복적인 뉴클레오티드 서열을 갖는 핵산
AU2016343979A1 (en) Delivery of central nervous system targeting polynucleotides
AU780854B2 (en) Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
US20030024009A1 (en) Manipulation of the phenolic acid content and digestibility of plant cell walls by targeted expression of genes encoding cell wall degrading enzymes
KR20210151916A (ko) 뒤시엔느 근육 이영양증의 치료를 위한 aav 벡터-매개된 큰 돌연변이 핫스팟의 결실
KR101591887B1 (ko) 장기 지속형 약물 제형
CN111733174B (zh) 一种分离的核酸分子及其用途
PT1984512T (pt) Sistema de expressão génica utilizando excisão-união em insetos
AU2024204421A1 (en) Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia
KR20210005146A (ko) 유전자 편집된 t 세포에서의 인간 foxp3의 발현
KR101970428B1 (ko) 재조합 볼거리 바이러스 제릴린2계 백신
CN115768890A (zh) 通过分子和物理启动对t细胞免疫疗法的热控制
CN101652475A (zh) 在禽类中进行转基因表达
KR20210151785A (ko) 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
CA2502664A1 (en) Sirna mediated gene silencing in transgenic animals
CN112203697A (zh) 编码氨基己糖苷酶alpha和beta亚基的双顺反子AAV载体及其用途
US6465715B1 (en) Expression of DNA or proteins in C. elegans